Tesamorelin

Description

Tesamorelin is a synthetic analogue of Growth Hormone-Releasing Hormone (GHRH) comprising 44 amino acids. It is modified with a trans-3-hexenoic acid group at the N-terminus, a structural alteration that significantly increases its stability and half-life compared to natural GHRH.

This peptide is unique in the research community for its specific affinity for reducing Visceral Adipose Tissue (VAT)—the deep, metabolically active fat surrounding the organs. Unlike general weight loss agents, Tesamorelin is investigated for its ability to selectively target this stubborn abdominal tissue while simultaneously elevating Insulin-Like Growth Factor 1 (IGF-1) levels, making it a premier compound for body composition and metabolic health research.

Key Research Applications

• Visceral Fat Reduction: Tesamorelin is most famous for its lipolytic effects on visceral fat. Clinical studies (originally in HIV-associated lipodystrophy models) demonstrated that Tesamorelin administration could significantly reduce visceral adipose tissue without altering subcutaneous fat or muscle mass, highlighting a unique mechanism of “targeted” fat mobilization.

• IGF-1 Optimization: It is a potent stimulator of the pituitary gland, causing a pulsatile release of growth hormone which downstream increases plasma IGF-1 levels. This makes it a subject of interest for researching muscle maintenance, tissue repair, and bone density in aging populations.

• Cognitive Function (Nootropic Potential): Because GHRH receptors are found throughout the brain, recent studies are investigating Tesamorelin for its potential to improve cognitive function, executive function, and verbal memory in subjects with mild cognitive impairment.

⚠️ FOR RESEARCH PURPOSES ONLY This product is intended for laboratory research and development use only. It is not intended for human consumption, diagnostic, or therapeutic use. Handle with care and adhere to all laboratory safety protocols.